Probiotics as therapeutic agents in irritable bowel syndrome;Probiotika in der therapie des reizdarmsyndroms

Zeitschrift fur Gastroenterologie

Volumn 43, Issue 5, 2005, Pages 467-471

  Krammer, Heinz J ^a   Schlieger, F ^a   Harder, H ^a   Franke, A ^a   Singer, M V ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Intestinal flora; Irritable bowel syndrome; Probiotics

Indexed keywords

PROBIOTIC AGENT;

ABDOMINAL PAIN; BIFIDOBACTERIUM BREVE; BLOATING; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI; HUMAN; INTESTINE FLORA; IRRITABLE COLON; LACTOBACILLUS; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS CASEI; LACTOBACILLUS PLANTARUM; NONHUMAN; REVIEW; TREATMENT OUTCOME;

FOLLOW-UP STUDIES; HUMANS; IRRITABLE BOWEL SYNDROME; LACTOBACILLUS CASEI; LACTOBACILLUS PLANTARUM; PROBIOTICS; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 20044381294     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-813934     Document Type: Review

References (32)

1. Hotz J, Enck P, Goebell H et al. Konsensusbericht: Reizdarmsyndrom - Definition, Diagnosesicherung, Pathophysiologie und Therapiemöglichkeiten. Konsensus der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten. Z Gastroenterol 1999; 37: 685-700
2. McKendrick MW, Read NW. Irritable bowel syndrome - post salmonella infection. J Infect 1994; 29: 1-3
3. Gwee KA, Graham JC, McKendrick MW et al. Psychometric scores and persistence of irritable bowel after infectious diarrhoea. Lancet 1996 (20); 347 (8995): 150-153
4. Neal KR, Hebden J, Spiller R. Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients. BMJ 1997; 314: 779
5. Rodruígez LAG, Ruigómez A. Increased risk of irritable bowel syndrome after bacterial gastroenteritis: cohort study. BMJ 1999; 318: 565-566
6. Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 2000; 95 (12): 3503-3506
7. Parry SD, Stansfield R, Jelley BS et al. Is irritable bowel syndrome more common in patients presenting with bacterial gastroenteritis? A communitiy-based, case-controll-study. Am J Gastroenterol 2003; 98 (2): 327-331
8. Thornley JP, Jenkins D, Neal K et al. Relationship of Campylobacter toxigenity in vitro to the development of postinfectious irritable bowel syndrome. J Infect Dis 2001; 184: 606-609
9. Spiller RC, Jenkins D, Thornley JP et al. Increased rectal mucosal enterendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000; 47: 804-811
10. Spiller RC. Estimating the importance of infection in IBS. Am J Gastroenterol 2003; 98 (2): 238-241
11. King TS, Elia M, Hunter JO. Abnormal colonic fermentation in irritable bowel syndrome. Lancet 1998; 352 (10): 1187-1189
12. Treem WR, Naheedt A, Kastoff G et al. Fecal short-chain fatty acids in patients with diarrhea-predominant irritable bowel syndrome: in vitro studies of carbohydrate fermentation. J Pediatr Gastroenterol Nutr 1996; 23 (3): 280-286
13. Balsari A, Ceccarelli A, Dubini F et al. The fecal microbial population in the irritable bowel syndrome. Microbiologica 1982; 5: 185-194
14. Swidinski A, Khilkin M, Ortner M et al. Alteration of bacterial concentration in colonic biopsies from patients with irritable bowel syndrome (IBS). Gastroenterology 1999; 116: A1
15. Koebnick C, Wagner I, Leitzmann P et al. Probiotic beverage containing Lactobacillus casei Shirota improves gastrointestinal symptoms in patients with chronic constipation. Can J Gastroenterol 2003; 17 (11): 655-659
16. Malcolm A, Kellow JE. Motility. Current Opinion in Gastroenterology 1997; 13: 117-123
17. Roberfroid M. Dietary fiber, inulin, and oligofructose: a review comparing their physiologic effects. Crit Rev Food Sci Nutr 1993; 33: 103-148
18. Spanhaak S et al. The effect of milk fermented by Lactobacillus casei Shirota on the intestinal microflora and immune parameters in humans. Eur J Clin Nutr 1998; 52: 899-907
19. Cummings JH et al. Prebiotic digestion and fermentation. Am J Clin Nutr 2001; 73 (Suppl): 415S-420S
20. Heaton KW et al. Defecation frequency and timing, and stool form in the general population: a prospective study. Gut 1992; 33: 818-824
21. Halpern GM, Prindiville T, Blankenburg M et al. Treatment of irritable bowel syndrome with Lacteol Fort: a randomized, double-blind, cross-over trial. Am J Gastroenterol 1996; 91 (8): 1579-1585
22. Nobaek S, Johansson ML, Molin G et al. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol 2000; 95 (5): 1231-1238
23. Niedzielin K, Kordecki H, Birkenfeld B. A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol 2001; 13: 1143-1147
24. Sen S, Mullan MM, Parker TJ et al. Effect of Lactobacillus plantarum 299 V on colonic fermentation and symptoms of irritable bowel syndrome. Dig Dis Sci 2002; 47 (11): 2615-2620
25. O'Sullivan MA, O'Morain CA. Bacterial supplementation in the irritable bowel syndrome. A randomized double-blind placebo-controlled crossover study. Digest Liver Dis 2000; 32: 294-301
26. Saggioro A. Probiotics in The Treatment of Irritable Bowel Syndrome. J Clin Gastroenterol 2004; 38: S104-106
27. Möllenbrink M, Bruckschen E. Behandlung der chronischen Obstipation mit physiologischen Escherichia-coli-Bakterien. Ergebnisse einer klinischen Studie zur Wirksamkeit und Verträglichkeit der mikrobiologischen Therapie mit dem E.-coli-Stamm Nissle 1917 (Mutaflor®). Medizinische Klinik 1994; 89 (11): 587-593
28. Bruckschen E, Horosiewicz H. Chronische Obstipation. Vergleich von mikrobiologischer Therapie und Lactulose. MMW 1994; 136 (16): 241-245
29. Gade J, Thorn P. Paraghurt for patients with Irritable Bowel Syndrome. Scand J Prim Health Care 1989; 7: 23-26
30. Hunter JO, Lee AJ, King TS et al. Enterococcus faecium strain PR88 - an effective probiotic. Gut 1996; 38 (Suppl): A62
31. Brigidi P, Vitali B, Swennen E et al. Effects of probiotic administration upon the composition and enzymatic activity of human fecal microbiota in patients with irritable bowel syndrome or functional diarrhoea. Res Microbiol 2001; 152: 735-741
32. Kim HJ, Camilleri M, McKinzie S et al. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2003; 17: 895-904